Psoriasis
- Mendelian Randomization is a Powerful Tool for Improving Psoriasis Understanding
- Machine Learning Accurately Predicts Biologic Discontinuation in Psoriasis
- Smoking Independently Associated With Higher Risk for Psoriasis
- Women With axSpA and PsA Have Higher Risk for Cesarean Section
- FDA Approves Biosimilar Hyrimoz High-Concentration Formulation
- Moderate to Severe Psoriasis Symptoms Improved With Anti-IL-17A Biologics
- Biologics May Reduce Psoriatic Arthritis Development in Patients With Psoriasis
- Bimekizumab Better Improves Nail Psoriasis vs Secukinumab
- Factors Associated With Worse COVID-19 Outcomes Among Patients With PsA, axSpA
- Switching to Guselkumab Safe After Ustekinumab Failure in Psoriasis
- Secukinumab Improves Clinical Response in Plaque Psoriasis
- Complete Skin Clearance May Lead to Long-Term Psoriasis Management
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
